Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07297654 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

First-Line Lenvatinib in Child-Pugh B Patients With HCC Unsuitable for Curative Treatment

Study acronym: FINELAND
StatusNot Yet Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Collaborators expanded, about 19 wordsv2
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This study aims to evaluate the efficacy and safety of lenvatinib as first-line therapy in patients with Child-Pugh class B HCC who are unsuitable for curative treatment.
Trial Details
NCT Number NCT07297654
Lead Sponsor National Cancer Center, Korea
Collaborators: Asan Medical Center, Seoul National University Hospital, Seoul National University Bundang Hospital, Samsung Medical Center, Hanyang University Guri Hospital
Conditions
(from sponsor)		 Advanced Hepatocellular Carcinoma
Enrollment 50 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov